Myeloproliferative Disorders Support
The newest options
Trials offer access to unproven but potentially beneficial therapies.JAK2 inhibitor drugs are under trial in several countries and are showing promise in improving quality of life for people with myelofibrosis. Other treatments are under trial for people with essential thrombocythaemia and polycythaemia vera – and we hope to find drugs that are more effective while causing fewer side effects.
If you are interested in enrolling in a trial, your first step is to talk with your haematologist. You may also wish to learn more about what drug trials are all about. If you need more information please email us at info@mpdvoice.org.uk
You can also watch a video interview of Albert, who is enrolled in a JAK2 inhibitor trial. You can read about people who are taking the newest drugs in Real Stories.
Trials open for myelofibrosis
In the United Kingdom
- COMFORT 2 now closed In 2009 a JAK2 inhibitor study called COMFORT 2 opened in the UK. This trial of the drug INC424 in patients with myelofibrosis opened the places filled rapidly and it closed early in 2010.
- Pomalidomide study to open In 2011 a study with pomalidomide will open for patients needing regular blood transfusions.
- Additional studies Further JAK inhibitor studies are likely to open later in 2011
In the United States
You can learn more about the JAK2 inhibitor trials from several organisations in the United States.
- MPN Research Foundation (US) The MPN Research Foundation (US) raises funds for MPD research and reports on clinical trials, press releases from biotech and pharmaceutical companies and the latest discoveries.
- NIH The National Institutes of Health In the US offers detailed and accurate information on diseases and a search tool to find clinical trials internationally.
- NCI The National Cancer Institute (NCI)’s clinical trials page offers detailed information on trials taking place in the US – search by disease name, for instance “myelofibrosis”.
Trials open for polycythaemia vera
In the United Kingdom
- Vorinostat study closed A study with Vorinostat opened and closed in 2010-early 2011
- Pegasys to open Studies with PEGASYS are likely to open later this year.
- JAK2 inhibitors study to open A study with the JAK inhibitor INC424 is scheduled to open in March
In the United States
- NIH The National Institutes of Health In the US offers detailed and accurate information on diseases and a search tool to find clinical trials internationally.
- NCI The National Cancer Institute (NCI)’s clinical trials page offers detailed information on trials taking place in the US – search by disease name, for instance “myelofibrosis”.
Trials open for essential thrombocythaemia
In the United Kingdom
- PT-1 trials The PT-1 trials remain open for patients with ET aged between 18 and 60. For more details visit the University of Cambridge PT-1 trial page
- Vorinostat closed A study with Vorinostat opened and closed in 2010-early 2011
- Pegasys trial to open Studies with PEGASYS are likely to open later this year.
In the United States
- NIH The National Institutes of Health In the US offers detailed and accurate information on diseases and a search tool to find clinical trials internationally.
- NCI The National Cancer Institute (NCI)’s clinical trials page offers detailed information on trials taking place in the US – search by disease name, for instance “myelofibrosis”.
Pregnancy survey in ET, PV and MF
Many women with a myeloproliferative disorder are young adults in their child bearing years. These women face unique challenges as they start families – risks to their own health and their unborn child. The Guy’s and St Thomas’ NHS Foundation Trust (GSTT) is opening the first UK-wide survey of pregnancy in myeloproliferative disorders in 2010. Visit the Pregnancy Survey page to learn more.